Seaport Therapeutics is implementing risk mitigation strategies in its Phase 2b clinical trial for SPT-300, an experimental treatment for major depressive disorder. The biotech company is designing the study with built-in safeguards to address potential trial challenges.
The approach reflects growing industry awareness of high failure rates in depression drug development, where clinical trials often struggle to demonstrate efficacy. Seaport executives appear to be positioning the company for multiple potential outcomes from the Phase 2b study.